BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Onbrez Breezhaler indacaterol: Phase III data

In the double-blind, international Phase III INSIST trial in 1,123 patients ages 40 and older, 150 µg once-daily indacaterol was superior to 50 µg twice-daily salmeterol on the primary endpoint of significantly improving FEV1 AUC from 5 minutes to 11 hours 45 minutes post-dose at week 12. Specifically, the adjusted mean difference in FEV1 AUC between treatment groups was 60 mL (p<0.001). Additionally, indacaterol was superior to salmeterol on the secondary endpoints of significantly improving trough FEV1 (p<0.001) and transition dyspnea index total score...

Read the full 397 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >